Rabbit Recombinant Monoclonal Securin antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
IHC-P | WB | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/5000 | Notes - |
Select an associated product type
Regulatory protein, which plays a central role in chromosome stability, in the p53/TP53 pathway, and DNA repair. Probably acts by blocking the action of key proteins. During the mitosis, it blocks Separase/ESPL1 function, preventing the proteolysis of the cohesin complex and the subsequent segregation of the chromosomes. At the onset of anaphase, it is ubiquitinated, conducting to its destruction and to the liberation of ESPL1. Its function is however not limited to a blocking activity, since it is required to activate ESPL1. Negatively regulates the transcriptional activity and related apoptosis activity of TP53. The negative regulation of TP53 may explain the strong transforming capability of the protein when it is overexpressed. May also play a role in DNA repair via its interaction with Ku, possibly by connecting DNA damage-response pathways with sister chromatid separation.
EAP1, PTTG, TUTR1, PTTG1, Securin, Esp1-associated protein, Pituitary tumor-transforming gene 1 protein, Tumor-transforming protein 1, hPTTG
Rabbit Recombinant Monoclonal Securin antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Securin also known as PTTG1 (pituitary tumor-transforming gene 1) is a protein involved in the regulation of sister chromatid separation during cell division. It inhibits Separase an enzyme important for this separation. Securin has a molecular mass of approximately 22 kDa. Its expression is notable in various tissues including the pituitary gland and cancerous tissues which suggests a role in tumorigenesis.
Securing proper chromosome segregation Securin forms a complex with Separase. By inhibiting Separase Securin ensures that separation of chromatids occurs only at the correct stage of mitosis. This regulatory function is critical for maintaining genomic stability and avoiding aneuploidy which can lead to tumorigenesis. The presence of Securin in dividing cells highlights its role in the cell cycle.
Securin functions are integrated within the cell cycle and apoptosis pathways. In the cell cycle pathway Securin controls the metaphase-anaphase transition. This involves interaction with cyclin-dependent kinases (CDKs) and the anaphase-promoting complex (APC/C). In terms of apoptosis Securin may interact with proteins like Bcl-2 impacting cell survival and death decisions under stress conditions.
Securin has been associated with cancer particularly pituitary adenomas and colorectal cancer. Its overexpression can lead to chromosomal instability a hallmark of many cancers. Furthermore interactions with other proteins like p53 known for its tumor-suppressing activities suggest a complex interplay in oncogenic processes where disruptions can contribute to tumor development and progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
IHC image of Securin staining in a section of formalin-fixed paraffin-embedded normal human testis tissue*, performed on a Leica BONDTM. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab199239, 1/1000 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab199239 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-Securin antibody [EPR3240] (ab199239) at 1/5000 dilution
All lanes: Daudi (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 22 kDa
Observed band size: 28 kDa
Exposure time: 16min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com